What happened
West Pharmaceutical Services, Inc. (NYSE: WST) signed a credit agreement on Oct. 26 covering an initial $950 million of loans and other financial accommodations.
The agreement covers Revolver A, Revolver B and a Term A Facility, with $200 million in Term A Loan commitments. West is the only borrower on the Term A loan as of the closing date. Certain subsidiaries also borrow under the agreement.
Key numbers
| Metric | Latest | Change | Source |
|---|---|---|---|
| Initial aggregate principal amount of loans and other financial accommodations | $950 million | SEC 8-K, Exhibit 10.1 credit agreement | |
| Term A Loan commitments | $200 million | SEC 8-K, Exhibit 10.1 credit agreement | |
| Term A share of initial total | 21.1% | Calculated from SEC 8-K | |
| Term A margin over Term SOFR, lowest tier | 1.125% | SEC 8-K, Exhibit 10.1 credit agreement | |
| Cap on unrestricted cash netted against debt | $400 million | SEC 8-K, Exhibit 10.1 credit agreement |
Read more: West Pharmaceutical Services (WST) company research
Why it matters
The financing leaves the operating question in the investment case unchanged. OptimistFi has argued that West's stock works only if high-value biologics demand and premium component economics reaccelerate after the recent margin reset. A credit agreement moves neither.
OptimistFi calculates that the Term A loan is 21.1% of the initial total, so most of the agreement sits in its other parts.
Borrowing costs are tied to leverage. Until West delivers the compliance certificate for the quarter ended March 31, 2027, margins stay at the lowest tier. That is 1.000% over Term SOFR on revolver loans and 1.125% on the Term A loan.
At a net leverage ratio of 3.50 to 1.0 or higher, those margins rise to 1.500% and 1.750%. After the first certificate, the cost of both loans will move with West's net leverage ratio.
The commitment fee follows the same tiers, from 0.125% to 0.225%. When West measures net debt, it can subtract at most $400 million of unrestricted cash and cash equivalents from total debt.
Stock perps: every US stock that trades as a perpetual future, by leverage, live
What's next
The next test is the compliance certificate for the quarter ended March 31, 2027. Until West delivers it, margins and the commitment fee stay at the lowest tier, so current pricing is provisional.
A net leverage ratio below 1.00 to 1.0 would keep West at the lowest tier. A ratio of 3.50 to 1.0 or higher would move margins to the top tier and weaken the financing picture.
More from OptimistFi
- WST stock: research and coverage of West Pharmaceutical Services
- Stock research on every company OptimistFi covers
From OptimistFi Perps
- Prop firms that fund crypto and stock perps traders: rules, prices and payouts
- Top perps movers today: stocks, commodities, FX and indices
- Open interest live: crypto and stock perps by exchange
- All perp markets: price, open interest and funding by venue
- Futures calculator: liquidation price, PnL and fees by exchange
Sources
- SEC Form 8-K, Exhibit 10.1: Credit Agreement dated as of October 26, 2026 — Credit agreement among West Pharmaceutical Services, Inc., certain subsidiaries, Bank of America, N.A. as administrative agent, and the lenders.
- SEC filing
Explore OptimistFi research on West Pharmaceutical Services, Inc.: https://optimistfi.com/stocks/WST
Browse West Pharmaceutical Services, Inc. company coverage and explore the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
Find available research on the West Pharmaceutical Services, Inc. company page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.
